Humana (NYSE:HUM) had its price objective cut by Morgan Stanley from $331.00 to $315.00 in a research report released on Friday morning, BenzingaRatingsTable reports. The brokerage currently has an overweight rating on the insurance provider’s stock.
HUM has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Hollysys Automation Technologies from a hold rating to a sell rating in a research report on Thursday, April 11th. SunTrust Banks boosted their price objective on shares of Markel to $1,100.00 and gave the company a hold rating in a research report on Thursday, May 2nd. Oppenheimer lowered their price objective on shares of Littelfuse from $215.00 to $210.00 and set an outperform rating for the company in a research report on Thursday, May 2nd. UBS Group set a $36.00 target price on shares of Halliburton and gave the stock a buy rating in a research report on Tuesday, April 23rd. Finally, Barclays set a $24.00 target price on shares of Tenet Healthcare and gave the stock a hold rating in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Humana presently has a consensus rating of Buy and a consensus target price of $336.42.
Shares of NYSE:HUM opened at $285.32 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40. Humana has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The firm’s 50-day simple moving average is $260.25. The company has a market cap of $39.33 billion, a P/E ratio of 19.61, a PEG ratio of 1.20 and a beta of 0.87.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, beating analysts’ consensus estimates of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The business had revenue of $16.11 billion during the quarter, compared to the consensus estimate of $15.67 billion. During the same quarter in the prior year, the firm earned $3.36 EPS. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, analysts expect that Humana will post 17.48 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is presently 15.12%.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Humana by 1.6% in the first quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after acquiring an additional 186,997 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Humana by 3.5% in the first quarter. Janus Henderson Group PLC now owns 3,596,204 shares of the insurance provider’s stock valued at $956,594,000 after acquiring an additional 120,905 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Humana by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock valued at $507,198,000 after acquiring an additional 135,776 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Humana by 0.5% in the first quarter. Northern Trust Corp now owns 1,743,519 shares of the insurance provider’s stock valued at $463,775,000 after acquiring an additional 8,221 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Humana in the fourth quarter valued at approximately $402,117,000. Institutional investors and hedge funds own 92.51% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Institutional Investors
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.